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PakistanAbstract Drug–drug interactions (DDIs) may result in the alteration of therapeutic response.
Sometimes they may increase the untoward effects of many drugs. Hospitalized cardiac patients
need more attention regarding drug–drug interactions due to complexity of their disease and thera-
peutic regimen. This research was performed to ﬁnd out types, prevalence and association between
various predictors of potential drug–drug interactions (pDDIs) in the Department of Cardiology
and to report common interactions. This study was performed in the hospitalized cardiac patients
at Ayub Teaching Hospital, Abbottabad, Pakistan. Patient charts of 2342 patients were assessed for
pDDIs using MicromedexDrug Information. Logistic regression was applied to ﬁnd predictors of
pDDIs. The main outcome measure in the study was the association of the potential drug–drug
interactions with various factors such as age, gender, polypharmacy, and hospital stay of the
patients. We identiﬁed 53 interacting-combinations that were present in total 5109 pDDIs with
median number of 02 pDDIs per patient. Overall, 91.6% patients had at least one pDDI; 86.3%
were having at least one major pDDI, and 84.5% patients had at least one moderate pDDI.
Among 5109 identiﬁed pDDIs, most were of moderate (55%) or major severity (45%); established
(24.2%), theoretical (18.8%) or probable (57%) type of scientiﬁc evidence. Top 10 common pDDIs
included 3 major and 7 moderate interactions. Results obtained by multivariate logistic regression
revealed a signiﬁcant association of the occurrence of pDDIs in patient with age of 60 years or more
(p< 0.001), hospital stay of 7 days or longer (p< 0.001) and taking 7 or more drugs (p< 0.001).
We found a high prevalence for pDDIs in the Department of Cardiology, most of which were of
Potential drug–drug interactions among hospitalized cardiac patients 221moderate severity. Older patients, patients with longer hospital stay and with elevated number of
prescribed drugs were at higher risk of pDDIs.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug related problems such as adverse drug reactions, drug–
drug interactions, idiosyncratic reactions, and hypersensitivity
reactions remained a major challenge in clinical practice
(Kra¨henbu¨hl-Melcher et al., 2007). Potential drug–drugs inter-
actions (pDDIs) are observed to be one of the most frequently
appearing challenge that may alter the pharmacokinetic and
pharmacodynamics of the drugs thus alter the overall thera-
peutic response (Baxter and Preston, 2010; Rodrigues, 2013).
Many adverse events can be prevented by identifying pDDIs
(Hansten and Horn, 2007). However, certain conditions such
as multiple disorders, chronic diseases and polypharmacy
may increase the risk of pDDIs (Miranda et al., 2011). The
consequences of pDDIs are highly variable from minor events
to severe events that can be fatal (Baxter and Preston, 2010).
Studies have shown that up to 27.0% of the patients admitted
in hospital have complications that are the outcomes of DDIs
(Janchawee et al., 2005). Studies have revealed that DDIs are a
major clinical problem along with other adverse drug reactions
especially in the hospitalized cardiac patients (Passarelli et al.,
2005; Uijtendaal et al., 2014).
Various studies suggest that cardiovascular patients are
more often reported with pDDIs as compared to patients with
other diseases (Ismail et al., 2013a,b; Ismail et al., 2012a,b).
The possible reason behind higher pDDI rate in cardiovascular
diseases may include elder age, multiple drug regimen, and
pharmacokinetic or pharmacodynamic nature of drugs used
in cardiology (Faulx and Francis, 2008). Cardiovascular drugs
are more often involved in pDDIs (Baxter and Preston, 2010;
Mendell et al., 2011). For example the drug–drug interactions
involving platelet inhibitors such as warfarin is often reported
in clinical practice, which may cause ﬂuctuations in prothrom-
bin time (Tadros and Shakib, 2010). DDIs with anticoagulant
drugs such as aspirin and clopidogrel are often result in
reinfarction or bleeding (Juurlink et al., 2009; Yusuf et al.,
2001). There are a few risk factors associated with pDDIs. It
has been noticed in various studies that people with older
age were at higher risk for exposure of more chronic condi-
tions as this age group usually have multiple diseases and are
prescribed with multiple number of medications as well
(Gagne et al., 2008). A study reported that 558 (26.5%) of
elder people taking medicines were exposed to at least one
DDI (Secoli et al., 2010). Polypharmacy and longer hospital
stay also inﬂuence the incidence rate of pDDIs (Gagne et al.,
2008). It was reported that164 (75.9%) patients taking 7 or
more drugs were having at least one pDDI while 76 (73.8%)
patients with hospital stay of seven or more were at risk of
DDIs (Ismail et al., 2011).
Although drug–drug interactions are common in the car-
diac patients, but there exists no practical mechanism for
reporting a drug–drug interaction in government hospitals of
Pakistan (Ismail et al., 2013a,b; Ismail et al., 2012a,b).1.1. Aim of the study
The main objectives of our study were to identify pDDIs in
the patient charts of cardiac patients admitted in a teaching
hospital, to ﬁnd the prevalence and types of pDDIs in The
Department of Cardiology ATH, to make list of most
common pDDIs in the hospitalized cardiac patients and
to determine the risk factors associated with pDDIs in
cardiology.
1.2. Ethical approval
The study protocol was approved by the Ethical Committee of
the Department of Pharmacy, COMSATS Institute of
Information Technology Abbottabad, Pakistan. Permission
to conduct this study in the Department of Cardiology was
also obtained from hospital administration of Ayub
Teaching Hospital Abbottabad.
2. Methods
This is a cross-sectional descriptive study carried at the
Department of Cardiology of the Ayub Teaching Hospital
(ATH), Abbottabad for a one year period from 01.01.2013
to 31.12.2013. There is no computerized hospital system at
ATH for dispensing of medicines or for reduction of med-
ication errors. Unfortunately the pharmacists appointed at
ATH are not assigned proper duty of providing pharmaceuti-
cal care or medication management for the patients.
2.1. Study population
A total of N= 3043 patient charts were screened for the male
and female patients admitted in the Department of
Cardiology, ATH during the year 2013. A minimum one day
hospital stay with at least two prescribed drugs was outlined
as the main criteria for the inclusion of the patient prescription
to the study sample. All the patients not complying these two
main criteria’s were excluded from the study. In addition, all
those patients who had incomplete data such as gender, age,
diagnosis, duration of hospital stay, date of admission and dis-
charge were excluded from our study. Upon applying the
inclusion and exclusion criteria, a sample of n= 2342 patient
charts was considered for the assessment. Hospital administra-
tion of ATH maintains patient record on their forms called
patient charts. Our concerned data were obtained from patient
charts. The data obtained included patient age, gender,
hospital stay, number of drugs used, main diagnosis, and all
prescribed drugs during his/her stay at the hospital. Most of
the drugs were prescribed with their trade names. We used
Pharmaguide to determine generic names of such drugs
(Neeshat, 2013).
Table 1 General patient characteristics.
Patient characteristics Frequency (%)
Gender
Male 1291 (55.1)
Female 1051 (44.9)
Age (years)
614 17 (0.7)
15–30 62 (2.6)
31–45 200 (8.5)
46–59 945 (40.4)
P60 1118 (47.7)
Median (years) 62
Range (years) 12–100
Hospital stay (days)
63 497 (21.2)
4–6 1030 (44)
P7 815 (34.8)
Median (days) 6
Range (days) 1–20
Number of prescribed medications
64 44 (1.9)
5–6 682 (29.1)
P7 1616 (69)
Median (drugs) 8
Range (drugs) 1–18
Main diagnosis
Myocardial Infarction (MI) 770 (32.9)
Coronary Artery Disease (CAD) 531 (22.7)
Acute Coronary Syndrome (ACS) 427 (18.2)
Others* 614 (26.2)
Table 2 Prevalence of pDDIs in the department of
cardiology.
Type of prevalence Frequency: n (%)
Severity of pDDIs
Overalla 2145 (91.6)
Majorb 2021 (86.3)
Moderateb 1979 (84.5)
Number of pDDIs per patient
None 197 (8.4)
1–2 1704 (72.8)
3–5 339 (14.5)
P6 102 (4.4)
Total pDDIs (n= 5109)
Median 2
Range 1–14
a Overall prevalence stands for occurrence of at least one pDDI
despite of severity-type.
b A single prescription may contain both type of interactions i.e.
at least one major and at least one moderate interaction as well.
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Patient charts were screened for pDDIs using Micromedex
free version for Microsoft Windows 8 by Truven Health
Analytics Inc. We considered all drugs given to patients includ-
ing all regular and PRN (pro re nata: as required) during their
whole hospital stay, that is, from their admission to discharge
in the hospital. Based on the severity, pDDIs were classiﬁed
into three main types;
 Contraindicated: The drug-pair is contraindicated for the
patient.
 Major: Such interaction may have risk of death and/or may
result in some serious negative outcome.
 Moderate: It may have harmful effect on patient’s condition
and can require change in the prescription.
Furthermore the scientiﬁc evidence of the pDDIs was docu-
mented using the following three classiﬁcations
 Established: Research conducted under well controlled
studies have strongly demonstrated the existence of
interaction.
 Theoretical: Researchers suggest that the interaction exists
but there is no proof of well-controlled studies.
 Probable: There is no strong evidence present, but health
care professionals suspect that there may have interaction
on the basis of their observations or pharmacology of drugs.
2.3. Data analyses
Frequencies and percentages are used to represent gender, age
group, duration of hospital stay and number of drugs used by
the patients. Median and ranges are also used accordingly.
Multivariate logistic regression analysis is done to determine
the association of occurrence of potential drug–drug interac-
tions with speciﬁed risk factors including gender, age, hospital
stay and number of drugs prescribed. P-value of 0.05 or less
was deemed statistically signiﬁcant. SPSS for Windows version
20 (SPSS, Inc., Chicago, IL, USA) was employed for all
statistical analyses.
3. Results
More than three thousand patients were admitted in the
Department of Cardiology during the study period. Among
them 2342 patients were studied. Among the studied patients
1291 (55.1%) were male and 1051 (44.9%) were female; med-
ian age was 62 years; median hospital stay was 6 days and
median number of prescribed medications was 8 (Table 1).
Most common diagnosis was myocardial infarction followed
by acute coronary syndrome and coronary artery disease
(Table 1).
Upon analysis, a total of 5109 numbers of pDDIs and 53
types of interacting combinations were identiﬁed. Overall,
2145 (91.1%) patients had a minimum of one pDDI regardless
of type of severity; 2021 (86.3%) and 1979 (84.5%) patients
were having at least one pDDI of major and moderate severity,
respectively (Table 2). Contraindicated types of pDDIs were
not found in any patient. In most of the cases 1–2 pDDIsper patients were identiﬁed with median of 2 pDDI. The iden-
tiﬁed pDDIs were classiﬁed on the basis of severity and scien-
tiﬁc evidence. Table 3 shows these types for 5109 numbers of
pDDIs. Among 5109 pDDIs, most were of moderate (2810,
55%) or major severity (2299, 45%); probable (2912, 57%),
established (1238, 24.2%) or theoretical (959, 18.8%) type of
scientiﬁc evidence.
Table 3 Levels of identiﬁed pDDIs.
Level Frequency: n (%)
Severity
Major 2299 (45.0)
Moderate 2810 (55.0)
Documentation (Scientiﬁc Evidence)
Established 1238 (24.2)
Theoretical 959 (18.8)
Probable 2912 (57.0)
Table 5 Predictors associated with pDDIs.
Variable Total number of
patients: n= 2342
Multivariate
Interaction
present
(n= 2145)
Interaction
absent
(n= 197)
OR
(95% Cl)
P-value
Patient age (years)
<60 1069 155
>60 1076 42 0.243 (0.167–0.353) <0.001
Gender
Female 965 86
Male 1180 111 0.857 (0.616–1.193) 0.361
Hospital stay (days)
<7 1359 168
>7 786 29 0.230 (0.150–0.354) <0.001
Number of drugs
<7 564 162
>7 1581 35 0.063 (0.043–0.093) <0.001
OR= Odds ratio; CI = Conﬁdence interval.
Exposure to potential drug–drug interactions (pDDIs) was the
dependent variable in the model (0 = absent, 1 = present). The
following variables were included in the model as predictors of
pDDIs: patient’s age (1 = below 60 years, 0 = 60 years or older),
gender (1 = male, 0 = female), hospital stay (1 = less than 7 days,
0 = 7 days or above), and number of drugs (1 = less than 7 drugs,
2 = 7 or above).
p=< 0.001 was considered statistically signiﬁcant.
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were also identiﬁed during the pDDIs. Few of the most
frequently occurring pDDIs despite of their clinical signiﬁ-
cance found in our study are presented in Table 4. Top 10
frequently occurring pDDIs included 3 major and 7 moderate
types of pDDIs. Furthermore to identify predictors of
pDDIs, a multivariate logistic regression analysis for the
association of pDDIs with various risk factors (Table 5) was
used. It was revealed that patient age of sixty years or more
(p=< 0.001; OR= 0.263; 95% Cl = (0.167–0.353)) was sig-
niﬁcantly associated with pDDI events. Moreover, hospital
stay of seven days or longer (p=< 0.001; OR= 0.230;
95% Cl = 0.150–0.354) and those patients taking 7 or more
drugs (p=< 0.001; OR = 0.063; 95% Cl = 0.043–0.093)
were also found signiﬁcantly associated with pDDI events.
4. Discussion
The prevalence of pDDIs in our study was very 91.6%. Few
years ago, a similar study was performed in the Department
of Cardiology, Hazara, Pakistan which showed overall
77.5% pDDI prevalence rate among randomly selected cardiac
patients (Ismail et al., 2012b). A study in the south Indian hos-
pital showed that prevalence rate for pDDIs was 30.67%
among the studied cardiac patients (Patel et al., 2011).
According to a study carried out in the cardiac ward of a hos-
pital in Nepal 32 out of the 150 studied cardiac patients had at
least one pDDI with prevalence rate of 21.3% (Sharma et al.,
2014). 43.4% prevalence rate for pDDIs was observed during
the study in the cardiac patients at an Iranian hospital
(Namazi, 2012). Few other studies also suggest that cardiac
patients are at higher risk of pDDIs as a number of cardiac
drugs are associated with pDDIs as these patients are more
vulnerable to pDDIs due to complexity of disease and multipleTable 4 Top 10 pDDI combinations.
pDDI Combination Severity
Aspirin + Clopidogrel Major
Clopidogrel + Fondaparinux Major
Aspirin + Fondaparinux Major
Aspirin + Bisoprolol Moderate
Aspirin + Ramipril Moderate
Aspirin + Nitroglycerin Moderate
Hydrochlorothiazide + Ramipril Moderate
Aspirin + Furosemide Moderate
Aspirin + Lisinopril Moderate
Atorvastatin + Clopidogrel Moderatedrug therapy (Albadr et al., 2014; Smithburger et al., 2010;
Straubhaar et al., 2006). Researchers have found that the drugs
commonly involved in pDDIs include cardiac glycosides,
NSAIDs, diuretics and calcium channel blockers (Queneau
et al., 2007). These studies show that pDDIs are one of most
important issues in cardiac patients.
Our study reported the median number of two pDDIs in
the cardiac patients. A study held earlier at ATH reported
similar median number of pDDIs in cardiac patients (Ismail
et al., 2012b). The median number of pDDIs in our study
was in accordance with previous studies. Some other studies
found similar median for pDDIs in cardiac patients (Bacic-
Vrca et al., 2010; Straubhaar et al., 2006). It was revealed in
our study that 55% of pDDIs in cardiac patients were of mod-
erate severity and 45% with major severity. A previous study
in cardiac patients at ATH also found a number of pDDIs.Documentation Frequency
Probable 489
Theoretical 423
Theoretical 414
Probable 380
Established 268
Probable 230
Probable 180
Probable 146
Established 142
Established 128
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had major severity (Ismail et al., 2012b). Majority of cardiac
patients in Croatia were also found with moderate pDDI
severity (Bacic-Vrca et al., 2010).
Our study found some factors related with pDDIs that
include patients’ age, polypharmacy and long hospital stay.
Signiﬁcant associations of pDDIs with various factors have
also been found in different other studies. Our ﬁndings regard-
ing association of pDDIs with elder patients are supported by
other studies as well (Bacic-Vrca et al., 2010; Mallet et al.,
2007). It was reported in our study that old age is a risk factor
for pDDIs (p< 0.001). A study performed at Switzerland in
cardiovascular patients also showed that patients with old
age were at higher risk for pDDIs (Egger et al., 2007).
Another study carried out in patients taking antihypertensive
drugs in Medicaid population also found signiﬁcant associa-
tion of pDDIs with increase in age (Carter et al., 2002).
Long hospital stay is another factor associated with occur-
rence of pDDIs as reported in our study (p< 0.001).
According to the results obtained from a study conducted at
Brazil in hospitalized patients, it was found that patients with
longer hospital stay had signiﬁcant association with pDDIs
(Riechelmann et al., 2005). Some other studies found similar
association which support our ﬁndings which suggest that
longer hospital stay may increase the chances of pDDI occur-
rence (Moura et al., 2009; Patel et al., 2011). Patients taking
multiple drugs in our study were at higher risk of pDDIs
(p< 0.001). A study held at Switzerland in a cardiac ward
found that incidence of pDDIs increased with increase in
number of drugs prescribed (Egger et al., 2007). Another study
performed at USA in patients with hypertension reported simi-
lar association (Carter et al., 2004). Few other studies have
also found similar association of polypharmacy with incidence
of pDDIs (Chatsisvili et al., 2010; Cruciol-Souza and
Thomson, 2006b; Gagne et al., 2008; Janchawee et al., 2005;
Riechelmann et al., 2005).
There was no signiﬁcant association of pDDIs with speciﬁc
gender in our study. Various studies have found different
results regarding association of any gender with risk of
pDDIs. A study held in cardiac patients of ATH had found
signiﬁcant association of pDDIs with male patients (Ismail
et al., 2012b). On the other hand, a signiﬁcant association of
pDDIs was found with female patients in another study per-
formed in Brazil (Cruciol-Souza and Thomson, 2006a).
There are many studies which support our ﬁndings. A study
in Italy revealed that pDDIs are not associated with any speci-
ﬁc gender (Nobili et al., 2009). Our ﬁndings suggest that
pDDIs are associated with elder patients, increased number
of drugs and patients with longer hospital stay.
The pharmacist role regarding clinical outcomes of various
adverse events is very important as pDDIs are a signiﬁcant
factor for hospitalization of patients. A clinical pharmacist
can help in the improvement of pharmacotherapy. A clinical
pharmacist can ﬁnd factors that may result in irrational pre-
scriptions. Such factors are called ‘‘drug related problems’’
and may alter the desired effects of drugs (Azhar et al., 2009;
Hanlon et al., 2004; Viktil and Blix, 2008). The role of pharma-
cist in the developed world is well recognized but this profes-
sion is not well established in the developing countries
including Pakistan. The lack of proper role of pharmacist in
less developed countries is leading patients with higher ratio
of adverse drug events. If pharmacists are assigned with theirproper role it may result not only in avoiding adverse drug
events but also in reducing cost of hospitalization as well
(Albadr et al., 2014; Azhar et al., 2009).
4.1. Limitations
Limitation of this study is its duration which is just for one
year without any intervention component. In addition, another
issue that might have affected the results of current study is a
strict inclusion criteria due to which, approximately a quarter
of medical chart was excluded. It is possible that the cases
excluded might be representing a relevant subpopulation of
patients, and using missing value imputations authors have
assessed the predictors of pDDIs for this sample in a better
way. However, in the current situation it was not possible
for the researcher to predict how the excluded cases might have
inﬂuence the current results of study. Future studies addressing
the similar question should consider adding such case and
analysis using missing value imputations can give a better
understanding about the predictors for the pDDIs among
hospitalized patients. Moreover, the absence of in vitro models
in our study representing the actual physiological environment
also limits our ability to accurately ﬁnd the predictors in vivo
environment where multiple drugs are co-administered.
5. Conclusion
Our study concluded that the overall incidence of pDDIs was
very high in the Department of Cardiology. It was found that
incidence of pDDIs was associated with old age, polyphar-
macy and increased lengths of hospital stay. The development
of such data base in hospitals may help for the surveillance of
pDDIs in hospitalized cardiac patients.
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